Update shared on20 Aug 2025
Fair value Decreased 5.63%Despite notable improvements in net profit margin and revenue growth forecasts, the consensus analyst price target for Medexus Pharmaceuticals has been revised downward from CA$7.11 to CA$6.71.
What's in the News
- Medexus Pharmaceuticals received approval from US CMS for New Technology Add-On Payment (NTAP) reimbursement for GRAFAPEX™ (treosulfan) for Injection for fiscal year 2026.
- Eligible procedures using GRAFAPEX™ will qualify for a maximum NTAP reimbursement of $21,411 per case.
- The approval was one of only five NTAPs granted under the traditional pathway from thirteen total applications considered for fiscal year 2026.
Valuation Changes
Summary of Valuation Changes for Medexus Pharmaceuticals
- The Consensus Analyst Price Target has fallen from CA$7.11 to CA$6.71.
- The Net Profit Margin for Medexus Pharmaceuticals has significantly risen from 14.66% to 16.79%.
- The Consensus Revenue Growth forecasts for Medexus Pharmaceuticals has significantly risen from 9.7% per annum to 11.0% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.